Literature DB >> 32038920

Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?

Alice Mogenet1, Pascale Tomasini1, Laurent Greillier1, Fabrice Barlesi1.   

Abstract

Entities:  

Year:  2019        PMID: 32038920      PMCID: PMC6987344          DOI: 10.21037/tlcr.2019.05.10

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


× No keyword cloud information.
  21 in total

1.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Authors:  Justin F Gainor; Leila Dardaei; Satoshi Yoda; Luc Friboulet; Ignaty Leshchiner; Ryohei Katayama; Ibiayi Dagogo-Jack; Shirish Gadgeel; Katherine Schultz; Manrose Singh; Emily Chin; Melissa Parks; Dana Lee; Richard H DiCecca; Elizabeth Lockerman; Tiffany Huynh; Jennifer Logan; Lauren L Ritterhouse; Long P Le; Ashok Muniappan; Subba Digumarthy; Colleen Channick; Colleen Keyes; Gad Getz; Dora Dias-Santagata; Rebecca S Heist; Jochen Lennerz; Lecia V Sequist; Cyril H Benes; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman; Alice T Shaw
Journal:  Cancer Discov       Date:  2016-07-18       Impact factor: 39.397

2.  Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

Authors:  Aaron N Hata; Alice T Shaw; Satoshi Yoda; Jessica J Lin; Michael S Lawrence; Benjamin J Burke; Luc Friboulet; Adam Langenbucher; Leila Dardaei; Kylie Prutisto-Chang; Ibiayi Dagogo-Jack; Sergei Timofeevski; Harper Hubbeling; Justin F Gainor; Lorin A Ferris; Amanda K Riley; Krystina E Kattermann; Daria Timonina; Rebecca S Heist; A John Iafrate; Cyril H Benes; Jochen K Lennerz; Mari Mino-Kenudson; Jeffrey A Engelman; Ted W Johnson
Journal:  Cancer Discov       Date:  2018-04-12       Impact factor: 39.397

3.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  D Planchard; S Popat; K Kerr; S Novello; E F Smit; C Faivre-Finn; T S Mok; M Reck; P E Van Schil; M D Hellmann; S Peters
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

4.  Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.

Authors:  Annie Guérin; Medha Sasane; Jie Zhang; Kenneth W Culver; Katherine Dea; Roy Nitulescu; Eric Qiong Wu
Journal:  J Med Econ       Date:  2015-02-06       Impact factor: 2.448

5.  Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

Authors:  Benjamin J Solomon; Benjamin Besse; Todd M Bauer; Enriqueta Felip; Ross A Soo; D Ross Camidge; Rita Chiari; Alessandra Bearz; Chia-Chi Lin; Shirish M Gadgeel; Gregory J Riely; Eng Huat Tan; Takashi Seto; Leonard P James; Jill S Clancy; Antonello Abbattista; Jean-François Martini; Joseph Chen; Gerson Peltz; Holger Thurm; Sai-Hong Ignatius Ou; Alice T Shaw
Journal:  Lancet Oncol       Date:  2018-11-06       Impact factor: 41.316

6.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

7.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

8.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

9.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

Review 10.  ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients.

Authors:  Paul Hofman
Journal:  Cancers (Basel)       Date:  2017-08-12       Impact factor: 6.639

View more
  2 in total

1.  A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer.

Authors:  Xinyan Xu; Di Liu; Junmiao Wen; Jiayan Chen; Min Fan
Journal:  Transl Lung Cancer Res       Date:  2020-12

2.  Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.

Authors:  Hayato Mizuta; Koutaroh Okada; Mitsugu Araki; Jun Adachi; Ai Takemoto; Justyna Kutkowska; Kohei Maruyama; Noriko Yanagitani; Tomoko Oh-Hara; Kana Watanabe; Keiichi Tamai; Luc Friboulet; Kazuhiro Katayama; Biao Ma; Yoko Sasakura; Yukari Sagae; Mutsuko Kukimoto-Niino; Mikako Shirouzu; Satoshi Takagi; Siro Simizu; Makoto Nishio; Yasushi Okuno; Naoya Fujita; Ryohei Katayama
Journal:  Nat Commun       Date:  2021-02-24       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.